NIH Grant Success Rates Are Plummeting. Forward Funding Is the Mechanism Nobody Saw Coming.

March 28, 2026 · 6 min read

Arthur Griffin

At the National Cancer Institute, the odds of winning an NIH research grant have fallen from one in 10 to one in 25. Not because Congress slashed the budget — it actually increased NIH funding by $216 million for FY2026. Not because fewer scientists are applying — submission rates have held steady. The collapse in grant success rates traces to a single policy mechanism that most researchers never think about until it hits them: forward funding.

As Granted News reported, a survey of nearly 1,000 NIH-funded researchers found that 25 percent of labs have already cut staff. But staff cuts are a symptom. The underlying disease is a structural shift in how NIH distributes its $47.2 billion budget — a shift that is eliminating thousands of grants per year without a single line of legislation reducing the appropriation.

How Forward Funding Broke the Math

Here is how NIH grants traditionally worked. When NIH awards a five-year R01 grant for $1.5 million, it does not write a $1.5 million check on day one. It funds the first year — roughly $300,000 — from the current fiscal year's budget, then funds subsequent years from future appropriations. This approach lets NIH spread its budget across many more concurrent grants. If your annual budget is $35 billion and the average first-year cost of a new grant is $300,000, you can fund far more new projects each year than if you had to commit the full multi-year amount upfront.

Forward funding reverses this logic. Under forward funding, NIH commits the full multi-year cost of a grant from a single fiscal year's appropriation. A $1.5 million grant funded forward consumes $1.5 million from this year's budget rather than $300,000. The money is obligated immediately, even though the research will take five years to complete.

In FY2024, NIH forward-funded between 5 and 15 percent of its new grants. In FY2025, that proportion surged to approximately 40 percent. The result was arithmetic: NIH awarded 5,564 fewer grants in FY2025 than in FY2024 — an 8.6 percent decline — despite operating under roughly the same total budget.

The mechanism was not hidden. The Office of Management and Budget directed NIH to increase forward funding as a fiscal management tool, locking in multi-year commitments before potential future budget disputes could threaten ongoing research. The intent was to protect existing grantees from the uncertainty of annual appropriations cycles. The side effect was devastating for anyone trying to win a new award.

The FY2026 Budget Does Not Fix This

Congress gave NIH $47.2 billion for FY2026, a $216 million increase over the previous year — a 0.5 percent bump that amounts to a real decrease after adjusting for the 2 to 3 percent biomedical research inflation rate tracked by the NIH Biomedical Research and Development Price Index.

More critically, Congress capped FY2026 forward funding at FY2025 levels rather than reverting to FY2024 proportions. Legislators initially wanted to force NIH back to FY2024's 5 to 15 percent forward-funding rate, but the OMB successfully lobbied for the higher cap. This means 40 percent forward funding is now the baseline, not the aberration.

If the FY2025 trend holds, NIH will award an estimated 970 fewer new grants in FY2026 than it would have under FY2024 funding proportions. Across all NIH institutes, paylines — the funding score below which grants are automatically rejected — are tightening. At institutes where paylines were already competitive, the compression is brutal. Jeremy Berg, a former director of the National Institute of General Medical Sciences, put it plainly: even researchers doing extremely valuable work will be denied funding simply because the available pool has shrunk.

The Human Cost in Labs Across the Country

The STAT survey of nearly 1,000 NIH-funded researchers revealed the human dimension of these numbers. Twenty-two percent of respondents reported that their labs had rescinded offers to students, staff, or postdoctoral researchers. Eleven percent had reduced existing lab members' salaries. Multiple researchers described shutting down active projects and releasing trained personnel who cannot be rehired once funding resumes.

At Northwestern University, pharmacogenomics researcher Minoli Perera lost approximately $500,000 in NIH funding for a study examining how drug responses vary across ancestries. Half the money had already been spent building research infrastructure — databases, patient enrollment protocols, analytical pipelines — that now sits idle. The grant was terminated on grounds that its diversity-related research framing conflicted with administration priorities. The infrastructure investment, funded by taxpayer dollars, produces nothing.

In Ohio, a researcher who had secured NIH funding to launch a new endometriosis research lab saw the grant canceled weeks before her employment contract expires. In Baltimore, an HIV researcher's grant cancellation left clinical data from hundreds of patients in limbo — collected but unanalyzed, with no funding to complete the work the patients volunteered for.

These are not anecdotes from the margins of the research enterprise. They represent a pattern playing out in thousands of labs. The forward-funding mechanism means that even if every terminated grant were restored tomorrow, the total number of available new awards would still be lower than it was two years ago.

The Self-Censorship Problem

Beyond the budget arithmetic, researchers describe a subtler form of damage: self-censorship in grant applications. NIH has begun screening applications for language misaligned with administration priorities, creating uncertainty about which research topics remain fundable. Researchers report rewriting proposals to remove terms related to health equity, social determinants of health, and community-based participatory research — not because the science changed, but because the political environment made certain vocabulary risky.

This chilling effect is difficult to quantify but potentially more damaging than the funding cuts themselves. Basic biomedical research depends on investigators pursuing the questions they believe are most scientifically important. When researchers optimize their proposals for political palatability rather than scientific merit, the quality of the funded portfolio degrades in ways that will not become apparent for years — when the clinical interventions that should have emerged from today's basic research simply do not exist.

Sixteen of NIH's 27 institutes lack Senate-confirmed directors, and several advisory boards have undergone politically motivated personnel changes. The leadership vacuum compounds the self-censorship problem: without clear institutional guidance on which topics remain safe to pursue, individual researchers err on the side of caution, steering toward less controversial — and often less impactful — research questions.

What Grant Seekers Should Do Now

The researchers who will succeed in this environment are not the ones who wait for the funding landscape to improve. They are the ones who adapt their strategy to the landscape that exists.

Diversify across NIH institutes. Payline compression varies dramatically by institute. The National Cancer Institute's one-in-25 odds are the worst case. Other institutes — particularly smaller ones with less competitive applicant pools — maintain success rates closer to historical norms. If your research can be framed for multiple institutes, submit to the one where your percentile score is most competitive.

Target mechanisms that are less affected by forward funding. R21 exploratory grants, R03 small grants, and cooperative agreements use different funding structures than R01s. Some administrative supplements and competitive revisions are funded from existing grant budgets rather than new appropriations. These smaller mechanisms will not replace a full R01, but they can keep a lab operational while the funding environment stabilizes.

Build multi-source funding portfolios. NSF, DOD, DOE, ARPA-H, and private foundations are not subject to NIH's forward-funding constraints. The DOE Genesis Mission is funding interdisciplinary research that overlaps with NIH's biomedical portfolio. The SBIR/STTR programs, newly reauthorized with $30 million Strategic Breakthrough Awards, offer non-dilutive funding for translational research. Researchers who treat NIH as their only funding source face existential risk in the current environment.

Time your submissions strategically. NIH review cycles have not changed, but the effective competitiveness of each cycle has. Early-cycle submissions that arrive when review panels are fresh and paylines have not yet been finalized may have marginal advantages over late-cycle submissions when remaining budgets are known to be tight.

The NIH funding crisis is structural, not cyclical. Forward funding at 40 percent is now locked in for FY2026, and there is no legislative vehicle on the horizon to force a return to historical norms. Researchers who build their funding strategies around this reality — rather than hoping it reverses — will be the ones whose labs survive.

For research teams navigating the new NIH landscape, Granted can help you identify alternative federal funding sources, match your research to programs across multiple agencies, and build the diversified funding portfolio that the current environment demands.

Get AI Grants Delivered Weekly

New funding opportunities, deadline alerts, and grant writing tips every Tuesday.

Browse all NIH grants

More NIH Articles

Not sure which grants to apply for?

Use our free grant finder to search active federal funding opportunities by agency, eligibility, and deadline.

Find Grants

Ready to write your next grant?

Draft your proposal with Granted AI. Win a grant in 12 months or get a full refund.

Backed by the Granted Guarantee